Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Block G, Liss C, Reines S, Irr J, Nibbelink D. Block G, et al. Among authors: reines s. Eur Neurol. 1997;37(1):23-7. doi: 10.1159/000117399. Eur Neurol. 1997. PMID: 9018028 Clinical Trial.
BACKGROUND: Motor response fluctuations and dyskinesias compromise long-term levodopa therapy in Parkinson's disease. Variations in plasma levodopa levels contribute to adverse reactions associated with chronic therapy. ...METHODS: Six hundred and eighteen nonfluctuating p …
BACKGROUND: Motor response fluctuations and dyskinesias compromise long-term levodopa therapy in Parkinson's disease. Variations in p …
Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Visser WH, et al. Among authors: reines sa. Arch Neurol. 1996 Nov;53(11):1132-7. doi: 10.1001/archneur.1996.00550110072014. Arch Neurol. 1996. PMID: 8912486 Clinical Trial.
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.
Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC; Rofecoxib Protocol 091 Study Group. Reines SA, et al. Neurology. 2004 Jan 13;62(1):66-71. doi: 10.1212/wnl.62.1.66. Neurology. 2004. PMID: 14718699 Clinical Trial.
BACKGROUND: Inflammatory mechanisms have been implicated in the pathogenesis of Alzheimer's disease (AD) and may be mediated via the cyclo-oxygenase-2 enzyme. ...The key efficacy measures were mean change from baseline at month 12 on the cognitive subscale of the AD Assess …
BACKGROUND: Inflammatory mechanisms have been implicated in the pathogenesis of Alzheimer's disease (AD) and may be mediated via the …
Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups.
Block GA, Goldstein J, Polis A, Reines SA, Smith ME. Block GA, et al. Among authors: reines sa. Headache. 1998 Nov-Dec;38(10):764-71. doi: 10.1046/j.1526-4610.1998.3810764.x. Headache. 1998. PMID: 11284464 Clinical Trial.
The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
Kramer MS, Last B, Getson A, Reines SA. Kramer MS, et al. Among authors: reines sa. Arch Gen Psychiatry. 1997 Jun;54(6):567-72. doi: 10.1001/archpsyc.1997.01830180085011. Arch Gen Psychiatry. 1997. PMID: 9193198 Clinical Trial.
A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.
Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP, McHugh W, Feighner J, Silberstein S, Reines SA. Kramer MS, et al. Among authors: reines sa. Neurology. 1998 Sep;51(3):773-81. doi: 10.1212/wnl.51.3.773. Neurology. 1998. PMID: 9748025 Clinical Trial.
Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.
Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, Jiang K, Reines S, Block G. Teall J, et al. Among authors: reines s. Headache. 1998 Apr;38(4):281-7. doi: 10.1046/j.1526-4610.1998.3804281.x. Headache. 1998. PMID: 9595867 Clinical Trial.
Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures.
Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A, Schmitt J, Yuen E, Reines S, Haas M. Faught E, et al. Among authors: reines s. Neurology. 2008 Nov 11;71(20):1586-93. doi: 10.1212/01.wnl.0000334751.89859.7f. Neurology. 2008. PMID: 19001248 Clinical Trial.
Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine.
Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P, Venkatraman S, Vrijens F, Malbecq W, Lines C, Visser WH, Reines S, Yuen E. Silberstein S, et al. Among authors: reines s. Neurology. 2004 May 11;62(9):1552-7. doi: 10.1212/01.wnl.0000123260.61631.c4. Neurology. 2004. PMID: 15136680 Clinical Trial.
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S. Hutton JT, et al. Among authors: reines s. Neurology. 1989 Nov;39(11 Suppl 2):67-72; discussion 72-3. Neurology. 1989. PMID: 2685652 Clinical Trial.
Controlled-release carbidopa/levodopa 50/200 (Sinemet CR) and standard carbidopa/levodopa (Sinemet 25/100) were compared in a multicenter double-blind trial involving 202 patients with advanced Parkinson's disease and motor response fluctuations. ...We conclude that Sineme …
Controlled-release carbidopa/levodopa 50/200 (Sinemet CR) and standard carbidopa/levodopa (Sinemet 25/100) were compared in a multicenter do …
52 results
Jump to page
Feedback